PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow

A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’

(2021) Alexandre Bazinet et al.   Expert Review of Hematology

The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation

(2021) Natalie Köhler et al.   Frontiers in Immunology

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

(2021) Julian Swatler et al.   Cancers

One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia

(2021) Zhiding Wang et al.   Frontiers in Immunology

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

(2020) Ivana Gojo et al.   BLOOD

Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS

(2020) Joshua F. Zeidner et al.   LEUKEMIA

Immune escape and immunotherapy of acute myeloid leukemia

(2020) Luca Vago et al.   JOURNAL OF CLINICAL INVESTIGATION

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

(2020) Delvys Rodriguez-Abreu et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel Treatment Paradigms in Acute Myeloid Leukemia

(2020) Nabin Khanal et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Regulation of PD-1 in T cells for cancer immunotherapy

(2020) Xibao Yu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

(2020) Li Xuan et al.   LANCET ONCOLOGY

Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia

(2020) Adam J. Lamble et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The tumor microenvironment

(2020) Nicole M. Anderson et al.   CURRENT BIOLOGY

Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells

(2020) Rachel Elizabeth Cooke et al.   Frontiers in Immunology

LAG-3: from molecular functions to clinical applications

(2020) Takumi Maruhashi et al.   Journal for ImmunoTherapy of Cancer

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

(2020) Joanne E. Davis et al.   Blood Advances

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets

(2019) Maximilian Stahl et al.   Current Oncology Reports

New Treatment Options for Acute Myeloid Leukemia in 2019

(2019) Marco Cerrano et al.   Current Oncology Reports

Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms

(2019) Jen-Chin Wang et al.   LEUKEMIA RESEARCH

Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia

(2019) Krzysztof Giannopoulos   Journal of Clinical Medicine

The Tumor Microenvironment Innately Modulates Cancer Progression

(2019) Dominique C. Hinshaw et al.   CANCER RESEARCH

Combination of CTLA-4 and PD-1 blockers for treatment of cancer

(2019) Anand Rotte   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

(2019) Lars Bastholt et al.   EUROPEAN JOURNAL OF CANCER

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

(2019) Farhad Ravandi et al.   Lancet Haematology

T-cell Immunoglobulin and ITIM Domain Contributes to CD8+ T-cell Immunosenescence

(2018) Yangzi Song et al.   AGING CELL

CD8 + T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients

(2018) Mengjie Wang et al.   CLINICAL IMMUNOLOGY

Advances in immunotherapy for acute myeloid leukemia

(2018) Amanda Przespolewski et al.   Future Oncology

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

(2018) Xiaolei Li et al.   Journal of Hematology & Oncology

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients

(2018) Bei Jia et al.   Blood Cancer Journal

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells

(2018) Nayoung Kim et al.   Frontiers in Immunology

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

(2018) Patrick Williams et al.   CANCER

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

(2018) Naval Daver et al.   Cancer Discovery

Higher Tim-3 expression concurrent with PD-1 in exhausted CD4+ and CD8+T cells in patients with acute myeloid leukemia

(2017) Jiaxiong Tan et al.   EXPERIMENTAL HEMATOLOGY

Neoplasms in the bone marrow niches: disturbance of the microecosystem

(2017) Li-Li Mu et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia

(2017) Liuluan Zhu et al.   Journal of Hematology & Oncology

TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia

(2017) Kemal Catakovic et al.   OncoImmunology

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients

(2016) Y. Kong et al.   CLINICAL CANCER RESEARCH

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

(2016) Matthew S. Davids et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment

(2015) Frauke M. Schnorfeil et al.   Journal of Hematology & Oncology

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

(2013) B. D. Curti et al.   CANCER RESEARCH

Bone marrow and the control of immunity

(2011) Ende Zhao et al.   Cellular & Molecular Immunology

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts

(2009) R. Le Dieu et al.   BLOOD

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH